What's new

Orphan designation: Glofitamab Treatment of diffuse large B-cell lymphoma, 15/10/2021 Withdrawn

Orphan designation: Glofitamab Treatment of diffuse large B-cell lymphoma, 15/10/2021 Withdrawn

Apr 9, 2025 - 09:27
 0
Orphan designation: Glofitamab Treatment of diffuse large B-cell lymphoma, 15/10/2021 Withdrawn
Orphan designation: Glofitamab Treatment of diffuse large B-cell lymphoma, 15/10/2021 Withdrawn
Read More

Tags:

Previous Article

Executive View: Humility and change lessons for Tesla's leadership

Next Article

Jubilee to increase yearly PGM output by 32% through excess stock partnership

Related Posts

Human medicines European public assessment report (EPAR): Torisel, temsirolimus, Date of authorisation: 19/11/2007, Revision: 35, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 3, 2025  0

Orphan designation: bexmarilimab Treatment of myelodysplastic syndromes, 25/03/2025 Positive

Orphan designation: bexmarilimab Treatment of myelodysp...

Apr 4, 2025  0

Human medicines European public assessment report (EPAR): Sugammadex Mylan, sugammadex, Date of authorisation: 15/11/2021, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 12, 2025  0